Carroll, N.; Youngblood, R.; Smith, A.; Dragoi, A.-M.; Salvatore, B.A.; Mahdavian, E.
TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors. Biomedicines 2022, 10, 2906.
https://doi.org/10.3390/biomedicines10112906
AMA Style
Carroll N, Youngblood R, Smith A, Dragoi A-M, Salvatore BA, Mahdavian E.
TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors. Biomedicines. 2022; 10(11):2906.
https://doi.org/10.3390/biomedicines10112906
Chicago/Turabian Style
Carroll, Natalie, Reneau Youngblood, Alena Smith, Ana-Maria Dragoi, Brian A. Salvatore, and Elahe Mahdavian.
2022. "TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors" Biomedicines 10, no. 11: 2906.
https://doi.org/10.3390/biomedicines10112906
APA Style
Carroll, N., Youngblood, R., Smith, A., Dragoi, A.-M., Salvatore, B. A., & Mahdavian, E.
(2022). TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors. Biomedicines, 10(11), 2906.
https://doi.org/10.3390/biomedicines10112906